TOKYO–(BUSINESS WIRE)–SUSMED, Inc. (TOKYO:4263) announced that “SUSMED SourceDataSync®” (“SUSMED SDS”), its proprietary blockchain-based clinical trial system, has contributed to obtaining marketing authorization for a pharmaceutical product1,2,3. This marks the world’s first pharmaceutical approval based on the results of an industry-sponsored clinical trial utilizing blockchain technology4. 1: https://newsroom.viatris.com/2026-09-16-Viatris-Announces-Approval-of-WAKIX-R-Pitolisant-in-Japan,